English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells

Garcia-Marquez, M. A., Shimabukuro-Vornhagen, A., Theurich, S., Kochanek, M., Weber, T., Wennhold, K., et al. (2014). A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells. Cytotherapy, 16(11), 1537-44. doi:10.1016/j.jcyt.2014.05.011.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-58E2-F Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-58E3-D
Genre: Journal Article

Files

show Files

Locators

show
hide
Description:
-

Creators

show
hide
 Creators:
Garcia-Marquez, M. A.1, Author
Shimabukuro-Vornhagen, A.1, Author
Theurich, S.1, Author
Kochanek, M.1, Author
Weber, T.1, Author
Wennhold, K.1, Author
Dauben, A.1, Author
Dzionek, A.1, Author
Reinhard, C.1, Author
von Bergwelt-Baildon, M.1, Author
Affiliations:
1Max Planck Institute for Biology of Ageing, Max Planck Society, Joseph-Stelzmann-Str. 9b, D-50931 Cologne, DE, ou_1942284              

Content

show
hide
Free keywords: Apc B cells Cd40l antigen presentation immunotherapy proliferation
 Abstract: BACKGROUND AIMS: CD40-activated B cells have long been studied as potent antigen-presenting cells that can potentially be used for cancer immunotherapy. Nevertheless, their use in human clinical trials has been limited by the lack of a Good Manufacturing Practice-grade soluble human CD40 ligand that is able to induce activation and proliferation of primary B cells. We describe an in vitro method to effectively generate and expand B cells through the use of a multimerized form of human recombinant CD40 ligand (rCD40L). METHODS: Human B cells were isolated from healthy donors and cultivated with either rCD40L or on a monolayer of murine NIH3T3 cells stably expressing human CD40L (NIH3T3/tCD40L) as a widely used standard method. Morphology, expansion rate, immune phenotype and antigen presentation function were assessed. RESULTS: B cells efficiently proliferated in response to rCD40L over 14 days of culture in comparable amounts to NIH3T3/tCD40L. B-cell division in response to CD40L was also confirmed by carboxyfluorescein succinimidyl ester dilution. Moreover, rCD40L induced on B cells upregulation of co-stimulatory molecules essential for antigen presentation. Additionally, proliferation of T cells from allogeneic healthy volunteers confirmed the immunostimulatory capacities of CD40-activated B cells. CONCLUSIONS: We demonstrated that B cells with potent antigen presentation capacity can be generated and expanded by use of a non-xenogeneic form of CD40L that could be implemented in future human clinical settings.

Details

show
hide
Language(s):
 Dates: 2014
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: Other: 25287602
DOI: 10.1016/j.jcyt.2014.05.011
ISSN: 1477-2566 (Electronic)1465-3249 (Linking)
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Cytotherapy
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 16 (11) Sequence Number: - Start / End Page: 1537 - 44 Identifier: -